Namodenoson Treatment of Advanced Pancreatic Cancer
Study sponsor: Can-Fite BioPharma
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2026-07-15Estimated
Enrollment · participants20Estimated
Source updated2025-01-31Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.